245 related articles for article (PubMed ID: 37004349)
1. Serum cytokines-based biomarkers in the diagnosis and monitoring of therapeutic response in patients with major depressive disorder.
Xu Y; Liang J; Sun Y; Zhang Y; Shan F; Ge J; Xia Q
Int Immunopharmacol; 2023 May; 118():110108. PubMed ID: 37004349
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood cytokines as potential diagnostic biomarkers of suicidal ideation in patients with first-episode drug-naïve major depressive disorder.
Xu Y; Liang J; Gao W; Sun Y; Zhang Y; Shan F; Ge J; Xia Q
Front Public Health; 2022; 10():1021309. PubMed ID: 36420006
[TBL] [Abstract][Full Text] [Related]
3. Comparison of serum cytokines levels in normal-weight and overweight patients with first-episode drug-naïve major depressive disorder.
Gao W; Xu Y; Liang J; Sun Y; Zhang Y; Shan F; Ge J; Xia Q
Front Endocrinol (Lausanne); 2022; 13():1048337. PubMed ID: 36387880
[TBL] [Abstract][Full Text] [Related]
4. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis.
Liu JJ; Wei YB; Strawbridge R; Bao Y; Chang S; Shi L; Que J; Gadad BS; Trivedi MH; Kelsoe JR; Lu L
Mol Psychiatry; 2020 Feb; 25(2):339-350. PubMed ID: 31427752
[TBL] [Abstract][Full Text] [Related]
5. Association between inflammatory cytokines and symptoms of major depressive disorder in adults.
Min X; Wang G; Cui Y; Meng P; Hu X; Liu S; Wang Y
Front Immunol; 2023; 14():1110775. PubMed ID: 36860860
[TBL] [Abstract][Full Text] [Related]
6. Effect of duloxetine on changes in serum proinflammatory cytokine levels in patients with major depressive disorder.
Gao W; Gao Y; Xu Y; Liang J; Sun Y; Zhang Y; Shan F; Ge J; Xia Q
BMC Psychiatry; 2024 Jun; 24(1):449. PubMed ID: 38877455
[TBL] [Abstract][Full Text] [Related]
7. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds.
Fornaro M; Rocchi G; Escelsior A; Contini P; Martino M
J Affect Disord; 2013 Mar; 145(3):300-7. PubMed ID: 22981313
[TBL] [Abstract][Full Text] [Related]
8. Serum Cortisol, Nesfatin-1, and IL-1β: Potential Diagnostic Biomarkers in Elderly Patients with Treatment-Resistant Depression.
Wu X; Dai B; Yan F; Chen Y; Xu Y; Xia Q; Zhang X
Clin Interv Aging; 2022; 17():567-576. PubMed ID: 35480963
[TBL] [Abstract][Full Text] [Related]
9. [Effect of Sertraline on Serum Cytokine Levels in Adolescents With First-Episode Major Depressive Disorder].
Xiang JJ; Hong S; Ran LY; Zeng Q; Kong YT; Zhang CY; Liao J; Kuang L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 54(2):310-315. PubMed ID: 36949691
[TBL] [Abstract][Full Text] [Related]
10. Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with major depression.
Zou W; Feng R; Yang Y
PLoS One; 2018; 13(6):e0197267. PubMed ID: 29856741
[TBL] [Abstract][Full Text] [Related]
11. Melancholic and atypical major depression--connection between cytokines, psychopathology and treatment.
Dunjic-Kostic B; Ivkovic M; Radonjic NV; Petronijevic ND; Pantovic M; Damjanovic A; Poznanovic ST; Jovanovic A; Nikolic T; Jasovic-Gasic M
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():1-6. PubMed ID: 23200828
[TBL] [Abstract][Full Text] [Related]
12. Cytokine profile in first-episode drug-naïve major depressive disorder patients with or without anxiety.
Liang J; Xu Y; Gao W; Sun Y; Zhang Y; Shan F; Xia Q
BMC Psychiatry; 2024 Feb; 24(1):93. PubMed ID: 38308225
[TBL] [Abstract][Full Text] [Related]
13. Prospective study on cytokine levels in medication-naïve adolescents with first-episode major depressive disorder.
Lee H; Song M; Lee J; Kim JB; Lee MS
J Affect Disord; 2020 Apr; 266():57-62. PubMed ID: 32056928
[TBL] [Abstract][Full Text] [Related]
14. Serum CC Chemokines as Potential Biomarkers for the Diagnosis of Major Depressive Disorder.
Gao W; Xu Y; Liang J; Sun Y; Zhang Y; Shan F; Ge J; Xia Q
Psychol Res Behav Manag; 2022; 15():2971-2978. PubMed ID: 36310625
[TBL] [Abstract][Full Text] [Related]
15. Machine Learning Analysis of Blood microRNA Data in Major Depression: A Case-Control Study for Biomarker Discovery.
Qi B; Fiori LM; Turecki G; Trakadis YJ
Int J Neuropsychopharmacol; 2020 Nov; 23(8):505-510. PubMed ID: 32365192
[TBL] [Abstract][Full Text] [Related]
16. The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder.
Lan X; Zhou Y; Wu F; Wu K; Zhan Y; Wang C; Zheng W; Yu M; Deng X; Ning Y
J Affect Disord; 2021 May; 287():327-333. PubMed ID: 33813252
[TBL] [Abstract][Full Text] [Related]
17. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder.
Rethorst CD; Toups MS; Greer TL; Nakonezny PA; Carmody TJ; Grannemann BD; Huebinger RM; Barber RC; Trivedi MH
Mol Psychiatry; 2013 Oct; 18(10):1119-24. PubMed ID: 22925832
[TBL] [Abstract][Full Text] [Related]
18. Potential value of Interleukin-6 as a diagnostic biomarker in human MDD and the antidepressant effect of its receptor antagonist tocilizumab in lipopolysaccharide-challenged rats.
Xu D; Xu Y; Gao X; Yan M; Zhang C; Wu X; Xia Q; Ge J
Int Immunopharmacol; 2023 Nov; 124(Pt B):110903. PubMed ID: 37717319
[TBL] [Abstract][Full Text] [Related]
19. Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis.
Shi Y; Luan D; Song R; Zhang Z
Eur Neuropsychopharmacol; 2020 Dec; 41():40-51. PubMed ID: 32980240
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of interleukin-8 and response to paroxetine in patients with major depressive disorder.
Guan X; Dong ZQ; Hao YN; Shen XL; Xie QL; Chen JM
Hum Psychopharmacol; 2022 Nov; 37(6):e2855. PubMed ID: 36194639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
